• 5 min read
• Published on 27 July 2025
Listen to article
6:16Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Every so often, a piece of news lands that sends the pharmaceutical world into a frenzy. This time, it’s the approval of a new Alzheimer's drug from Eli Lilly. The headlines are screaming about breakthroughs and miracle cures. And while that’s all well and good for patients and their families, I think most investors are looking at the wrong part of the picture. They see the shiny new drug, but they’re missing the vast, expensive, and frankly, mandatory machinery needed to get it into a single patient’s veins.
To me, the drug itself is just the ticket to the show. The real, long term opportunity might just be in selling the programmes.
Let’s be clear, this isn't like getting a prescription for antibiotics. You can’t just pop down to the chemist. Before a doctor can even think about prescribing these new treatments, a patient must jump through some serious hoops. First, they need sophisticated genetic testing. This isn't a nice to have, it's a requirement. The tests determine if the drug will even work for you, or more importantly, if it carries a higher risk of dangerous side effects.
Then comes the monitoring. These drugs can cause brain swelling, a rather unwelcome side effect, I’m sure you’ll agree. So, patients need regular brain imaging to keep an eye on things. What was once a diagnostic tool for special occasions has now become a routine part of the treatment plan. This creates an entire ecosystem of essential services, a tollbooth on the road to treatment that every single patient must pass through.
When you look at it this way, the investment case broadens considerably. Of course, you have the drug makers themselves, like Eli Lilly and its competitor Biogen, who have paved the way in neurology. They are the obvious front runners. But who is running the genetic screening? That would be companies like Illumina, whose sequencing technology suddenly becomes indispensable.
These support services are not just a footnote, they are the foundation of this new treatment model. They represent a recurring revenue stream that is, in my opinion, far more predictable than the boom and bust cycle of a single blockbuster drug. A drug patent eventually expires, but the need for a genetic test or a brain scan for every new patient? That seems a bit more durable. It’s the difference between selling someone a car and selling them a lifetime fuel and maintenance contract. I know which business I’d rather own.
Now, before we all get carried away, let’s pour a little cold water on the excitement. Investing in healthcare is never a straight line. Regulators could change their minds on a whim, altering testing requirements overnight. Competition is always lurking, and a new technology could disrupt the entire field. And of course, all investments carry risk, you could get back less than you put in.
Trying to pick the one winner in this complex web of drug makers, genetic testers, and imaging specialists feels like a bit of a fool’s errand. It’s why looking at the theme as a whole might be a more pragmatic approach. A diversified basket of companies involved in this revolution, such as the {{ $json.output.basketName }}, could offer exposure to the entire ecosystem, from the drug developers to the essential service providers. This approach spreads the risk, so you’re not betting the farm on a single company’s fortune. It’s a way to invest in the entire gold rush, not just one miner’s lucky strike.
View the full Basket:The Alzheimer's Treatment Ecosystem
View the full Basket:The Alzheimer's Treatment Ecosystem
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article